Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is Polaris Capital Management LLC’s 4th Largest Position

Polaris Capital Management LLC reduced its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 16.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,085,860 shares of the specialty pharmaceutical company’s stock after selling 219,700 shares during the period. Jazz Pharmaceuticals accounts for about 6.5% of Polaris Capital Management LLC’s investment portfolio, making the stock its 4th largest position. Polaris Capital Management LLC owned 1.80% of Jazz Pharmaceuticals worth $133,724,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of JAZZ. UMB Bank n.a. lifted its stake in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. GAMMA Investing LLC lifted its position in Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares in the last quarter. Itau Unibanco Holding S.A. lifted its position in Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after buying an additional 172 shares in the last quarter. Venturi Wealth Management LLC grew its stake in Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Jazz Pharmaceuticals by 56.7% in the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 350 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 5,053 shares of company stock valued at $617,442 over the last 90 days. 4.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. TD Cowen reduced their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $123.51 on Tuesday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market cap of $7.47 billion, a price-to-earnings ratio of 17.40, a PEG ratio of 0.92 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The stock has a 50 day moving average of $122.52 and a 200-day moving average of $116.53.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.